Through the utilization of peer-reviewed research combined with the knowledge of an ibogaine expert, a clinical practice has now refined its knowledge into a new document outlining the uses and treatment capabilities of a psychoactive drug with immense healing potential.
On Tuesday, Beond announced the release of its therapy research e-handbook entitled: Ibogaine: A Clinical Summary. Beond is a healthcare company that owns a series of five psychedelic therapy clinics in Mexico.
The new resource was created in collaboration with Thomas Kingsley Brown, Ph.D., an anthropologist who has been actively engaged with studying ibogaine since 2009. Kingsley has also been actively working as a researcher with the Multidisciplinary Association for Psychedelic Studies (MAPS) since 2010.
Read more: Cybin administers psychedelic analogue to patients with major depression
Read more: PharmAla Biotech applies for patent on 6 novel MDMA molecules
Ibogaine is a psychoactive medicine derived from root bark of the iboga (tabernanthe iboga) plant, a shrub native to Africa.
The handbook includes detailed discussion regarding the efficacy of ibogaine for a variety of usages, particularly for opiate and opioid addiction or substance use disorder. Additional information includes pharmacology, efficacy for treating behavioural conditions, the role of spirituality in the healing process, administration methods, possible side effects and overall safety.
Photo via Beond – Ibogaine therapy
“Ibogaine is the only treatment for opioid use disorder that consistently and significantly alleviates withdrawal symptoms that isn’t itself an opioid, and it does so with an effect level on par with methadone,” said Brown.
“Research also shows that ibogaine not only interrupts addiction in the short term but also helps people control their drug addiction in the long term, leading to cessation or substantial reductions in problematic drug use,” added Brown.
Beond and Brown say that they have made the new document publicly available for the good of prospective patients, professional researchers, psychedelic-assisted therapy practitioners and others.
Beond states that its therapy team includes licensed medical doctors, ICU-trained nurses and clinical psychologists with over five years of experience assisting patients with the necessary preparation prior to taking ibogaine, proper procedures for administration and after care regimens.
The network of Mexican psychedelic therapy clinics also says that it supports each client’s specific needs.
“We understand that for many people the decision of whether or not to utilize ibogaine-assisted treatment for chemical dependency or severe depression, anxiety, or trauma can be daunting,” said Tom Feegel, Co-Founder of Beond.
“Many of our clients report that this process can take months of research, leaving them to depend on claims from unverifiable sources, and can even lead to conflicting conclusions based on partial or incomplete information. Beond believes this outcome does a disservice to everyone seeking to understand Ibogaine and its potential benefits, and we seek to be a reliable, accessible resource for anyone seeking information about this powerful treatment.”
